A new treatment for a currently incurable group of inherited neurological diseases that affect 1 in 10000 children has been revealed, which works by triggering the body’s own ‘recycling’ system. New research by scientists at Orphazyme ApS, published in Science Translational Medicine, reveals a promising method to treat several diseases in the sphingolipidoses family of lysosomal storage diseases. These debilitating disorders, including Niemann-Pick type C, Fabry, and Sandhoff diseases, involve the accumulation of sphingolipids (fat molecules) in the cells and are often fatal during early childhood.